Navigation Links
Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
Date:10/12/2009

R Cysteamine through the clinic."

Under a license with UC San Diego, Raptor is developing DR Cysteamine for cystinosis, NASH and other potential therapeutic indications. Cysteamine is known to be a scavenger of reactive oxygen species and potent antioxidant, most likely through its ability to increase intracellular glutathione levels. Cysteamine has also demonstrated potential efficacy in preclinical and clinical studies in Huntington's Disease, Batten Disease and other indications.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Nasdaq: RPTPD) ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase ("ALDH2") deficiency, and a non-opioid solution designed to potentially treat chronic pain and thrombotic disorder.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human '/>"/>

SOURCE Raptor Pharmaceutical Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Raptor Pharmaceuticals Schedules 2009 Annual Meeting of Stockholders
2. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
3. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
4. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
5. Raptor Pharmaceuticals Closes $10 Million Private Placement
6. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
7. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
8. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
9. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
10. Raptor Pharmaceuticals Acquires Orphan Clinical Program
11. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... 27 Stallergenes has bee...n both adults and children,through a Mutual Recogn...Oralair(R) has been marketed, was the reference Me...d in Austria, Belgium, Bulgaria, Cyprus, the,Czech...ry, Ireland, Italy,Latvia, Lithuania, Luxembourg,...
(Date:11/26/2009)...new generation of ultrasmall transistors and more ...ed semiconducting nanowires are closer to reality ...e University and the University of California at L...o create nanowires with layers of different materi...which is a critical requirement for making efficie...
(Date:11/25/2009)...25 Biotech firm Replikins Ltd., wh... the 1918 pandemic through the prediction, outbrea...y issued its latest biochemical analysis of the vi...H1N1 ("Swine Flu") virus has dropped from its peak...reak in the spring of 2009 to resting non-epidemic...
(Date:11/25/2009)... ,, BOCA RATON, Fla., Nov. 25 F...Not so for BodyLogicMD. The nation,s largest and ...alizing exclusively in medically supervised bioid...icians in its network since November 2008 - fro... more physician-owned centers, including one in Pu...
Breaking Biology Technology:STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4
...Dynamic Alert,Limited (OTC Bulletin Board: DYMC) i...ts target markets for its pharmaceutical product l... some capacity for enhancing rapid onset,through o...s lotions and,salves, and various products for int...while others may treat a range of problems. In kee...
...l experience with the FDA,cleared Visica 2(TM) Tre...fectiveness of ultrasound guided cryoablation to c...l Breast Cancer (IDC). Initial data from this,mul...ic Assembly and Annual,Meeting of the Radiological...cember 5, 2008. , The study, "New Findings o...
...enesco Technologies, Inc. ("Senesco" or the "Compa... its Development and License Agreement with the h...erminated by mutual agreement because of Harris Mo... , , Harris Moran has reported that its paren...eed operations and that Harris Moran will now be p...
Other Biology Technology:Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 3Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 2Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA 3Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3
(Date:11/26/2009)...2009) Whitehead researchers have developed a new ... specific genes and proteins used by pathogens, ac...uman cell cultures genes are present in two copies...other. Gene inactivation by mutation is therefore ...the second copy usually remains active and takes o...
(Date:11/26/2009)...aphylococcus Aureus ) and other drug-resistant bac...lasma prototype devices have been developed to off...cktails. , Two prototype devices have been devel...in (e.g. hands and feet) in hospitals and public s... another to shoot bacteria-killing agents into inf...
(Date:11/25/2009)...the stomach, may be used to boost resistance to, o...le School of Medicine researchers report in a stud...euroscience . , Parkinson,s disease is caused by...the midbrain known as the substantia nigra, which ...roduction of dopamine in late-stage Parkinson,s ca...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Hormone ghrelin can boost resistance to Parkinson's disease 2Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 1Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 2Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 3Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 4Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 5Collexis BiomedExperts com Achieves 200 000 Registered Users 54873 1Collexis BiomedExperts com Achieves 200 000 Registered Users 54873 2Collexis BiomedExperts com Achieves 200 000 Registered Users 54873 3Eclipsemed Ltd to Introduce EndyMed PRO 28TM 29 to U S Aesthetic Market 54868 1Eclipsemed Ltd to Introduce EndyMed PRO 28TM 29 to U S Aesthetic Market 54868 2Eclipsemed Ltd to Introduce EndyMed PRO 28TM 29 to U S Aesthetic Market 54868 3
...niversity study suggests that evolution can behave...epend on an energy-efficient style of four-footed ...ats seem to have evolved a profoundly inefficient ...n slow motion. , "It is usually assumed that effi...Schmitt, a Duke associate professor of evolutionar...
...f children failing to take their medication for a ...ed as part of a new university research project. ,...at The University of Nottingham and The University...ol children with asthma, diabetes, congenital hear... that prevent them from taking medicines prescribe...
...3, 2008 Today, the International Society for Stem...sional organization of stem cell researchers, rele...t of safe and effective stem cell therapies for pa...uidelines for the Clinical Translation of Stem Cel... issue of Cell Stem Cell , the official affiliate...
Other Biology News:Dogs chase efficiently, but cats skulk counterintuitively 2A spoonful of sugar? 2A spoonful of sugar? 3The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3
...ial membrane potential. The mitochondrial permeabi... of the initiation of cellular apoptosis. This pro...ctrochemical gradient across the mitochondrial mem...otential (YD). Loss of mitochondrial YD is indicat...
...ed to detect poly(ADP-ribose) polymerase (PARP) cl...icated in DNA damage and repair mechanisms. During... of PARP from the native 116 kDa to 85 kDa is a ha...ighly specific rabbit polyclonal antibody that det...
...utter (controlled via a TTL signal or switch up to...ight Source combines the continuous spectrum of de...ngle optical path. The combined-spectrum light sou...0 nm. In addition, deep-UV versions of the light s...
Agilent MSD Security ChemStation for GC and GC/MS from Agilent Technologies
Biology Products: